XELOX for Metastatic Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/6/2018 |
| Start Date: | March 2005 |
| End Date: | November 2006 |
A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The
combination has improved activity in other solid tumors. This study seeks to assess the
activity of the combination in breast cancer.
combination has improved activity in other solid tumors. This study seeks to assess the
activity of the combination in breast cancer.
Inclusion Criteria:
- preserved organ function
- good performance status
- no more than one prior therapy
- no active brain metastasis
Exclusion Criteria:
- No prior capecitabine or oxaliplatin
- no con-current therapy
We found this trial at
1
site
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Click here to add this to my saved trials
